These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 38805583)
1. Hippo and PI5P4K signaling intersect to control the transcriptional activation of YAP. Palamiuc L; Johnson JL; Haratipour Z; Loughran RM; Choi WJ; Arora GK; Tieu V; Ly K; Llorente A; Crabtree S; Wong JCY; Ravi A; Wiederhold T; Murad R; Blind RD; Emerling BM Sci Signal; 2024 May; 17(838):eado6266. PubMed ID: 38805583 [TBL] [Abstract][Full Text] [Related]
2. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway. Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576 [TBL] [Abstract][Full Text] [Related]
3. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853 [TBL] [Abstract][Full Text] [Related]
4. Regulation of YAP by mechanical strain through Jnk and Hippo signaling. Codelia VA; Sun G; Irvine KD Curr Biol; 2014 Sep; 24(17):2012-7. PubMed ID: 25127217 [TBL] [Abstract][Full Text] [Related]
5. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling. Mana-Capelli S; McCollum D J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805 [TBL] [Abstract][Full Text] [Related]
6. Hippo pathway effectors YAP, TAZ and TEAD are associated with EMT master regulators ZEB, Snail and with aggressive phenotype in phyllodes breast tumors. Akrida I; Makrygianni M; Nikou S; Mulita F; Bravou V; Papadaki H Pathol Res Pract; 2024 Oct; 262():155551. PubMed ID: 39153238 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER Ma S; Tang T; Probst G; Konradi A; Jin C; Li F; Gutkind JS; Fu XD; Guan KL Nat Commun; 2022 Feb; 13(1):1061. PubMed ID: 35217640 [TBL] [Abstract][Full Text] [Related]
8. Hippo/Yap signaling controls epithelial progenitor cell proliferation and differentiation in the embryonic and adult lung. Lange AW; Sridharan A; Xu Y; Stripp BR; Perl AK; Whitsett JA J Mol Cell Biol; 2015 Feb; 7(1):35-47. PubMed ID: 25480985 [TBL] [Abstract][Full Text] [Related]
9. The phosphoinositide PI5P inhibits the Hippo pathway effector YAP. Baumann K Nat Rev Mol Cell Biol; 2024 Jul; 25(7):513. PubMed ID: 38858473 [No Abstract] [Full Text] [Related]
10. Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein. Li C; Srivastava RK; Elmets CA; Afaq F; Athar M Biochem Biophys Res Commun; 2013 Sep; 438(4):607-12. PubMed ID: 23942117 [TBL] [Abstract][Full Text] [Related]
11. A connection between phosphatidylinositol 5-phosphate and the Hippo pathway to prevent epithelial-mesenchymal transition in cancer. Hirsch E; Fantastico E; Prever L; Gulluni F Sci Signal; 2024 May; 17(838):eadp3504. PubMed ID: 38805585 [TBL] [Abstract][Full Text] [Related]
12. A conserved MST1/2-YAP axis mediates Hippo signaling during lung growth. Lin C; Yao E; Chuang PT Dev Biol; 2015 Jul; 403(1):101-13. PubMed ID: 25912685 [TBL] [Abstract][Full Text] [Related]
13. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy. Zhu J; Wu T; Lin Q Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351 [TBL] [Abstract][Full Text] [Related]